New T-cell therapy is expected to treat a variety of solid tumors March 19, 2018 Source: WuXi PharmaTech Adaptimmune Therapeutics, a biopharmaceutical company that develops new T-cell therapies, has announced that NY-ESO SPEAR T cell therapy has partially relieved patients with the first mucin-like round cell liposarcoma (MRCLS). This is also the second solid tumor treated by this new T cell therapy. This new platform technology is expected to achieve efficacy in a variety of solid tumors. Both MRCLS and synovial sarcoma are soft tissue sarcomas. MRCLS is a liposarcoma characterized by proliferation of adipocyte precursors and stagnation of differentiation. This malignant tumor is derived from the translocation of chromosomes 12 and 16, resulting in the fusion protein blocking adipocyte differentiation and promoting malignant transformation. Synovial sarcoma is characterized by a translocation of the X chromosome and chromosome 18, which is different from the origin of the immature adipocytes known by MRCLS, and the origin cells of synovial sarcoma are still unknown. It is estimated that there are approximately 2,000 MRCLS patients in the United States and Europe each year. MRCLS has the highest incidence among patients aged 30 to 50 years and is usually more aggressive than other liposarcomas. MRCLS also exhibits a unique metastatic pattern that first appears in the proximal extremities of the limbs, usually spreading to the bones (especially the spine), the serosal surface, the retroperitoneum, the abdomen, the pelvis, and other soft tissues. This mode of metastasis is different from the lung diffusion profile exhibited by synovial sarcoma. Adaptimmune's new cancer immunotherapy SPEAR (Specific Peptide Enhanced Affinity Receptor) T cell platform enables T cells to engineer and target cancer, including solid tumors. SPEAR T cells targeting MAGE-A4, -A10 and AFP are undergoing clinical trials in a variety of solid tumor indications. â–²Adaptimmune Therapeutics research and development pipeline (Source:Adaptimmune Therapeutics official website) The results reported recently showed that three of the top four patients had partial remission (two confirmed and one to be confirmed), and one patient was stable. Patients are well tolerated by cytokine release syndrome (CRS) according to standard treatment guidelines. "We are encouraged by the initial remission of MRCLS patients who have used NY-ESO SPEAR T cell therapy because it validates the potential of our platform to treat a wide range of tumors, including those that are not alleviated by existing immunotherapies," Adaptimmune Chief Medical Dr. Rafael Amado said: "Although MRCLS is a soft tissue sarcoma that normally expresses NY-ESO, its clinical course, natural history, molecular markers and reactivity to standard treatment are fundamentally different from synovial sarcoma. Together with more data from other trials, these results on the second solid tumor enhance our belief that our unique TCR pipeline will be able to solve a variety of solid tumors." We hope to hear more excellent data on this new T-cell therapy in the future and look forward to bringing new treatments to patients with refractory solid tumors. Reference materials: [1] Adaptimmune Sees Positive Early Results in Cancer Treatment [2] Adaptimmune shares boosted by new signs of success with TCR cell therapy [3] Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells Plant extracts refer to substances extracted or processed from plants (all or a part of plants) with appropriate solvents or methods, which can be used in pharmaceutical industry, food industry, daily chemical industry and other industries. Nowadays, the application range of plant extracts has been very wide. In addition to traditional Chinese medicine products, with the gradual increase of people's trust and reliance on natural products, a large part of plant extracts have been used in health care products and food ingredients. In addition, plant extracts have been used in cosmetics and feed in recent years. Andrographis Paniculata Extract,Hydrocotyle Asiatica Extract,Icariin,Reishi Mushroom Extract,Maca Root Extract Xi'an Gawen Biotechnology Co., Ltd , https://www.amulyn-bio.com
